Bill & Melinda Gates Foundation Commits $120m For Molnupiravir In Lower-Income Countries
Foundation Partners With Merck & Co On Developing Generic Versions Of Molnupiravir
Executive Summary
The Bill & Melinda Gates Foundation has extended a financial commitment of up to $120m to secure a dedicated, low-cost supply of generic molnupiravir to lower-income countries. The Gates Foundation is looking to “significantly reduce the time it takes for a new drug to reach low-income countries after it becomes available in high-income markets.”